Gå direkt till innehåll
Erika Gelfgren, CEO of Agrisera.
Erika Gelfgren, CEO of Agrisera.

Pressmeddelande -

Agrisera acquired by Uppsala life science company Olink

After many years of private ownership, Vännäs-based Agrisera has been acquired by Swedish biotech company Olink Proteomics AB.

“The Agrisera brand was very strong in itself, but this step offers us great opportunities that can benefit both our customers and partners,” says Erika Gelfgren, CEO of Agrisera.

Agrisera is a Swedish company specialising in the production of polyclonal and monoclonal antibodies.

“We provide a large range of ready-made antibodies, mainly for plant research, which are used, for example, to better understand photosynthesis,” explains Erika Gelfgren.

She continues: “We also provide reagents and secondary antibodies, as well as custom-made antibodies for researchers and companies in various research areas, including human medicine.”

Agrisera and Uppsala-based Olink have collaborated for several years, which resulted in a strong working relationship between the two companies. Olink has now acquired Agrisera from main shareholder Greger Nordlund, who founded Agrisera 35 years ago and held the position as the company’s CEO up until 2018.

“In addition to Greger we had a number of minority shareholders - all with links to Agrisera - who have now sold their shares,” says Erika Gelfgren, who believes the backing of their new owner will unlock significant new opportunities.

Following the acquisition, the plan is for Agrisera to continue operating as an independent unit without any major organisational changes. Erika Gelfgren will remain as CEO and the company will continue production from its site in Vännäs.

“However, with Olink by our side we have access to an expanded network which opens up new possibilities for collaboration that will help us further strengthen the life science sector in the Umeå region. We will continue to run our webshop and develop our product catalogue, while staying committed to placing the same high demands on all parts of our production chain. Agrisera stands for high-quality products and services, and we will continue to deliver that.”

Today Agrisera employs around 20 members of staff, but more may be recruited in the coming months.

“We are ramping up our production capacity and want to bring in new skills and knowledge to the company. We will definitely be expanding the workforce in the future,” says Erika Gelfgren.

For further information please contact:

Erika Gelfgren, CEO, Agrisera
erika@agrisera.com
070-534 27 60

Kategorier

Regioner


Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Kontakter

Tomas Ruuth

Tomas Ruuth

Presskontakt Kommunikationsansvarig PR & Communications 072-4024697 www.ubi.se

Relaterat innehåll

Joakim Vickman, new at UmanDiagnostics.

Recruitment drive at UmanDiagnostics continues as orders anticipated to rise

Last summer Umeå-based UmanDiagnostics was acquired by major US life science company Quanterix for $22.5 million. Now it is recruiting additional staff at its offices in Umeå to meet an expected rise in new orders. “We’re continuing to invest and are confident we’ll come out of the Coronavirus crisis even stronger, despite the uncertainty being faced by many industries,” says Niklas Norgren, CEO.

New and Different Facebook Group Helping Life Science Companies

New and Different Facebook Group Helping Life Science Companies

​A new Facebook group is enabling companies in Umeå to buy and sell second-hand laboratory equipment, as well as gain access to cheaper lab services. “Many life science companies are often in need of a laboratory, but new equipment is expensive and requires a great deal of knowledge to operate. This new group allows companies to sustainably support each other,” says Jennie Ekbeck, CEO of UBI.

Maja Johansson is new site manager at Diamyd Medical in Umeå.

Key appointments being made at new diabetes vaccine facility in Umeå

Construction of Diamyd Medical's new vaccine manufacturing unit in Umeå is now underway, with a number of key roles being actively recruited to help staff the new facility. Newly-appointed site manager Maja Johansson is responsible for establishing the process for the production of GAD, the active substance in the study drug Diamyd.

We grow ideas that can change the world

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Umeå Biotech Incubator

Tvistevägen 48C
907 36 Umeå
Sverige